VAISHALI PHARMA
|
VAISHALI PHARMA Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.67 | 6.26 | 3.82 | 0.99 | 0.03 |
| CEPS(Rs) | 0.11 | 0.67 | 0.42 | 0.14 | 0.04 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 33.41 | 31.26 | 24.99 | 21.26 | 20.27 |
| Tax Rate(%) | 22.37 | 25.35 | 29.76 | 25.51 | 58.56 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 1.93 | 13.46 | 9.08 | 4.92 | 1.50 |
| EBIT Margin(%) | 3.70 | 15.94 | 10.84 | 7.49 | 4.39 |
| Pre Tax Margin(%) | 1.07 | 12.70 | 7.56 | 2.61 | 0.13 |
| PAT Margin (%) | 0.83 | 9.48 | 5.31 | 1.95 | 0.05 |
| Cash Profit Margin (%) | 1.42 | 10.20 | 5.91 | 2.74 | 0.78 |
| Performance Ratios | |||||
| ROA(%) | 0.91 | 8.24 | 4.81 | 1.38 | 0.05 |
| ROE(%) | 2.09 | 22.26 | 16.50 | 4.78 | 0.15 |
| ROCE(%) | 5.82 | 21.92 | 18.87 | 10.33 | 6.89 |
| Asset Turnover(x) | 1.09 | 0.87 | 0.91 | 0.71 | 0.89 |
| Sales/Fixed Asset(x) | 22.31 | 19.49 | 24.50 | 19.16 | 24.69 |
| Working Capital/Sales(x) | 2.08 | 1.72 | 3.10 | 2.44 | 2.89 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.04 | 0.05 | 0.04 | 0.05 | 0.04 |
| Receivable days | 217.95 | 293.72 | 301.44 | 386.08 | 292.96 |
| Inventory Days | 7.25 | 9.64 | 2.93 | 4.98 | 5.65 |
| Payable days | 91.69 | 154.80 | 198.07 | 253.76 | 172.05 |
| Valuation Parameters | |||||
| PER(x) | 20.88 | 2.33 | 17.34 | 32.86 | 1,288.35 |
| PCE(x) | 122.35 | 21.65 | 15.57 | 23.34 | 89.63 |
| Price/Book(x) | 4.19 | 4.67 | 2.65 | 1.53 | 1.98 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.87 | 2.39 | 1.18 | 0.96 | 0.97 |
| EV/Core EBITDA(x) | 43.54 | 14.35 | 10.28 | 11.55 | 19.03 |
| EV/EBIT(x) | 50.47 | 15.00 | 10.85 | 12.78 | 22.20 |
| EV/CE(x) | 2.91 | 3.07 | 1.89 | 1.29 | 1.54 |
| M Cap / Sales | 1.74 | 2.21 | 0.92 | 0.64 | 0.70 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 23.85 | -8.12 | 41.00 | -10.50 | -19.98 |
| Core EBITDA Growth(%) | -68.11 | 33.82 | 94.60 | 45.00 | -24.35 |
| EBIT Growth(%) | -71.24 | 35.11 | 103.89 | 52.92 | -30.54 |
| PAT Growth(%) | -89.11 | 64.12 | 284.58 | 3,091.33 | -95.41 |
| EPS Growth(%) | -89.29 | 64.12 | 284.58 | 3,091.33 | -97.13 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.35 | 0.41 | 0.79 | 0.78 | 0.78 |
| Current Ratio(x) | 2.25 | 2.27 | 1.47 | 1.37 | 1.51 |
| Quick Ratio(x) | 2.24 | 2.17 | 1.46 | 1.36 | 1.49 |
| Interest Cover(x) | 1.41 | 4.92 | 3.30 | 1.53 | 1.03 |
| Total Debt/Mcap(x) | 0.08 | 0.09 | 0.30 | 0.51 | 0.39 |
Compare Financial Ratios of peers of VAISHALI PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VAISHALI PHARMA | ₹217.3 Cr | -1.8% | 4.5% | 2.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹419,764.0 Cr | 0.6% | -2.1% | 16.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,010.0 Cr | 4.3% | 6.5% | 63.9% | Stock Analytics | |
| CIPLA | ₹118,905.0 Cr | 3.6% | 0.2% | 2.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,523.0 Cr | 3% | -8.4% | 0% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹100,015.0 Cr | 3.2% | -1% | 27.4% | Stock Analytics | |
VAISHALI PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VAISHALI PHARMA | -1.8% |
4.5% |
2.6% |
| SENSEX | 0.5% |
0.3% |
7.9% |
You may also like the below Video Courses
